Oncology
Latest news
826 articles · 20 / page
Precision Post-CDK4/6i Management: Molecular Stratification Redefines Second-Line Therapy in HR+ Advanced Breast Cancer
This systematic review and network meta-analysis of 20 randomized trials demonstrate that molecular profiling for ESR1 and PI3K-AKT-PTEN alterations is essential for optimizing endocrine-based strategies after CDK4/6 inhibitor progression,
AXL: The Double-Edged Sword in Colorectal Cancer Treatment
Researchers have identified AXL expression as a critical biomarker in colorectal cancer. While it usually signals treatment resistance, a new study reveals that AXL-high tumors with KRAS mutations respond significantly better to immunothera
Low-Pass Whole Genome Bisulfite Sequencing for ctDNA Monitoring in Metastatic Colorectal Cancer: Insights from the VALENTINO Trial
This review evaluates the clinical utility of METER, a novel lp-WGBS workflow for ctDNA detection in RAS wild-type mCRC, demonstrating its prognostic value and cost-effectiveness in monitoring treatment response.
Low-Dose Pembrolizumab Matches Standard-of-Care Efficacy in Neoadjuvant TNBC: Insights from the PLANeT Trial
The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou
Precision Rechallenge: Liquid Biopsy CGP Refines Patient Selection in Metastatic Colorectal Cancer
The randomized CAVE-2 GOIM trial demonstrates that while adding avelumab to cetuximab rechallenge does not improve survival in metastatic colorectal cancer, liquid biopsy-based genomic hyper-selection identifies a subgroup of patients with
Advancing Adjuvant Care: Carboplatin Intensification in High-Risk Triple-Negative Breast Cancer
The CITRINE trial demonstrates that adding adjuvant carboplatin to standard chemotherapy significantly improves survival in high-risk triple-negative breast cancer patients, primarily by preventing early recurrence.
HSP90 Inhibition with XL888 Fails to Sensitize Metastatic Pancreatic Cancer to PD-1 Blockade Despite Systemic Immune Activation
A Phase Ib/II trial evaluating the combination of XL888 (an HSP90 inhibitor) and pembrolizumab in metastatic pancreatic adenocarcinoma found that while the regimen was safe and induced systemic immune modulation, it failed to alter the tumo
Trastuzumab Deruxtecan in HER2-Overexpressing NSCLC: Efficacy, Safety, and the Challenges of Combination Therapy in DESTINY-Lung03
This review analyzes the Phase 1b DESTINY-Lung03 trial results, highlighting the robust efficacy of trastuzumab deruxtecan monotherapy in HER2-overexpressing NSCLC and the prohibitive toxicity encountered when combined with durvalumab and p
Dual-Action ICyM2 Nano-Platform Dismantles Pancreatic Cancer Stromal Barriers and Ignites STING-Mediated Immunity
Researchers have developed ICyM2, a carrier-free nanoaggregate that combines mitochondrial phototherapy with STING activation. This platform effectively remodels the dense pancreatic cancer stroma, triggers immunogenic cell death, and syner
Integrating Local and Metastasis-Directed Therapies Redefines Survival in Oligometastatic Prostate Cancer: Evidence from an Umbrella Review
An umbrella review of 21 meta-analyses involving 160,000 patients confirms that prostate radiotherapy and metastasis-directed therapy significantly improve survival and progression control in oligometastatic prostate cancer, establishing a
High Ultra-Processed Food Consumption Linked to Increased Mortality Among Black Breast Cancer Survivors
A longitudinal study of 1,733 Black breast cancer survivors reveals that high intake of ultra-processed foods significantly increases both breast cancer-specific and all-cause mortality, highlighting a critical modifiable risk factor for ad
Multiantigen-Targeted T Cell Therapy Shows Durable Persistence and Clinical Activity in Advanced Pancreatic Cancer
A phase 1/2 trial demonstrates the safety and clinical potential of nonengineered, multiantigen-targeted T cell therapy for pancreatic ductal adenocarcinoma, highlighting durable T cell persistence and antigen spreading as key correlates of
AI-Derived Sarcopenia Metrics Predict Survival Benefit from Anti-EGFR Therapy in RAS Wild-Type Metastatic Colorectal Cancer
A deep learning analysis of the PanaMa trial reveals that the benefit of adding panitumumab to maintenance therapy for RAS wild-type mCRC is significantly higher in patients with a high muscle-bone ratio, suggesting a new AI-driven approach
Muscle-Bone Ratio: A New AI-Driven Biomarker for Anti-EGFR Response in Metastatic Colorectal Cancer
A deep learning-derived sarcopenia marker, the muscle-bone ratio (MBR), has been shown to predict the efficacy of anti-EGFR maintenance therapy in patients with RAS wild-type metastatic colorectal cancer, potentially identifying those who t
Adding Megestrol to Letrozole Enhances Antiproliferative Effects in ER+ Breast Cancer: Insights from the PIONEER Trial
The Phase 2b PIONEER trial reveals that adding megestrol to letrozole significantly reduces tumor proliferation in early-stage ER+ breast cancer. By reprogramming estrogen receptor activity, this combination offers a dual benefit of enhance
More Is Not Always Better: Long-term Data from the SAKK 09/10 Trial Refutes Dose-intensified Salvage Radiotherapy for Prostate Cancer
Long-term results from the SAKK 09/10 trial demonstrate that dose-intensified salvage radiotherapy (70 Gy) provides no oncological benefit over conventional dosing (64 Gy) in patients with biochemical recurrence after prostatectomy, while s
Beyond Detection: How ctDNA Dynamics Predict Treatment Success in Advanced Breast Cancer
The plasmaMATCH trial establishes ctDNA testing as a highly accurate tool for directing targeted therapies in advanced breast cancer. New data reveal that baseline ctDNA levels and early on-treatment dynamics serve as powerful prognostic ma
Rethinking the Standard: Is a Chemotherapy-Free Future Possible for HER2-Enriched Breast Cancer?
The WSG-KEYRICHED-1 trial investigates a chemotherapy-free regimen for HER2-enriched early breast cancer, showing that 47% of patients achieved a pathological complete response using only immunotherapy and dual HER2 blockade.
Optimizing Immunotherapy in Triple-Negative Breast Cancer: Reduced-Dose Folate Receptor Alpha Vaccine Shows Robust Efficacy Without Cyclophosphamide Pretreatment
A Phase II trial demonstrates that a reduced-dose Folate Receptor Alpha (FRα) vaccine is safe and highly immunogenic in triple-negative breast cancer patients, achieving robust T-cell responses comparable to high-dose regimens and eliminati
Elacestrant Reinforces Its Role in the Real-World Management of ESR1-Mutated Metastatic Breast Cancer
This real-world study demonstrates that elacestrant provides a durable benefit for patients with ER+/HER2- ESR1-mutated metastatic breast cancer, maintaining efficacy across various treatment lines and in patients with visceral metastases o
Browse by specialty
Open language-specific specialty feeds and department pages.